Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(Rac)-JBJ-04-125-02 (JBJ-04-125-02) is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 107.00 | |
5 mg | In stock | $ 228.00 | |
10 mg | In stock | $ 372.00 | |
25 mg | In stock | $ 629.00 | |
50 mg | In stock | $ 896.00 | |
100 mg | In stock | $ 1,220.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 276.00 |
Description | (Rac)-JBJ-04-125-02 (JBJ-04-125-02) is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer. |
Targets&IC50 | EGFR:0.26 nM |
In vitro | (Rac)-JBJ-04-125-02 is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M[1]. |
In vivo | The combination of osimertinib and JBJ-04-125-02 is a significantly more effective treatment approach than either agent alone[1]. |
Animal Research | Ba/F3, H1975, H3255GR and H3255DR cells were treated with increasing concentrations of inhibitors for 72 hours and growth or the inhibition of growth was assessed by MTS assay according to previously established methods. |
Synonyms | JBJ-04-125-02 |
Molecular Weight | 543.61 |
Formula | C29H26FN5O3S |
CAS No. | 2140807-05-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (101.17 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(Rac)-JBJ-04-125-02 2140807-05-0 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Allosteric anti-proliferation HER1 inhibit JBJ-04-125-02 ErbB-1 (Rac)JBJ0412502 Inhibitor racemate Epidermal growth factor receptor anti-tumor (Rac) JBJ 04 125 02 T790M-mutant inhibitor